Search Results

Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher upfront payments and the Big Pharmas seeking more expansive platform deals.

After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech.

Parabilis Medicines is joining the parade of biotechs going public, sharing plans to raise as much as $476.4 million to help advance its lead cancer candidate into late-stage testing.

Six biotechs based in California, Massachusetts, Washington and Denmark had to halt drug development efforts this year. One of their CEOs is now in an interim chief executive role at another biotech.

Biotech has been pulling off some remarkable science of late, while M&A and IPOs return to bolster the sector. But that doesn’t mean the industry is back from the brink. BioSpace gathered three early-stage biotech CEOs and members of the NextGen Class of 2026 to talk about surviving and thriving in this rollercoaster market, all while bringing forward the next generation of medicines.

In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to lead the agency after the departure of Marty Makary.

From Chinese innovation to AI, biotech CEOs are being hit with challenges at a breakneck pace. Three leaders from BioSpace’s NextGen Class of 2026 told us about the issues keeping them up at night.

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech entrepreneurs have BioSpace Senior Editor Annalee Armstrong feeling upbeat about the biotech scene.

Amidst rising layoffs in key biotech hubs, global demand for specialized life sciences talent is driving a more borderless, distributed model of scientific work.